Golden State Equity Partners Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Golden State Equity Partners increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 440.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,370 shares of the company’s stock after buying an additional 14,971 shares during the quarter. Golden State Equity Partners’ holdings in Johnson & Johnson were worth $2,657,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in JNJ. Avantra Family Wealth Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $262,000. Journey Strategic Wealth LLC increased its stake in Johnson & Johnson by 0.3% during the fourth quarter. Journey Strategic Wealth LLC now owns 7,038,858 shares of the company’s stock worth $1,017,960,000 after acquiring an additional 21,959 shares during the last quarter. Sylvest Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $793,000. SYM FINANCIAL Corp increased its stake in Johnson & Johnson by 16.0% during the fourth quarter. SYM FINANCIAL Corp now owns 8,050 shares of the company’s stock worth $1,164,000 after acquiring an additional 1,113 shares during the last quarter. Finally, Comprehensive Financial Consultants Institutional Inc. increased its stake in Johnson & Johnson by 4.0% during the fourth quarter. Comprehensive Financial Consultants Institutional Inc. now owns 28,267 shares of the company’s stock worth $4,088,000 after acquiring an additional 1,078 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.1 %

NYSE:JNJ opened at $153.54 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $147.53 and its two-hundred day moving average is $156.10. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a market cap of $369.66 billion, a PE ratio of 23.09, a P/E/G ratio of 2.44 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.23%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Guggenheim upped their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Bank of America lowered their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Finally, Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.